{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-107032","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.530071+00:00","generated_at":"2026-05-31T04:18:32.230832+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tivic Health Partners with Fletcher Spaght to Accelerate ncVNS Commercial Strategy","bullets":["Partnered with Fletcher Spaght, a healthcare growth strategy firm, to develop commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).","Fletcher Spaght identified ~30 potential use cases in neurologic, cardiac, psychiatric, and autonomic diseases.","Global VNS market projected to grow from $8.59B (2021) to $21.3B (2030) at 10.6% CAGR; peripheral nerve stimulation at 35% CAGR.","Tivic completed Phase 1 trial showing strong physiological effects in neurological, cardiac, and autonomic systems.","Company expects insights to drive clinical strategy and product development in 2025 and beyond."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-107032","json":"https://secwatch.observer/filing/0000950170-24-107032.json","markdown":"https://secwatch.observer/filing/0000950170-24-107032.md","text":"https://secwatch.observer/filing/0000950170-24-107032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024107032/0000950170-24-107032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024107032/tivc-20240916.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:18:32.230832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}